Pharmacy, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
Critical Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Eur J Hosp Pharm. 2023 May;30(3):136-141. doi: 10.1136/ejhpharm-2020-002618. Epub 2021 Jun 2.
Admission of complex and frail patients to critical care units is common. Little is known about the relationship between clinical frailty and polypharmacy measures in critical care patients or how a critical care admission affects polypharmacy.We sought to: (1) Describe the extent and relationship between clinical frailty and polypharmacy in a cohort of older emergency general critical care patients, and to (2) Describe the effect of the critical care pathway on patient polypharmacy measures.
A retrospective evaluation was undertaken in all patients ≥70 years of age, admitted as emergencies to the general critical care units of a single large UK academic hospital, over a 2-year period (March 2016 to February 2018) (n=762). Patient Clinical Frailty Scale (CFS) and polypharmacy measures on admission were described and association was tested. Medication changes and documentation on care transitions were analysed in a randomly selected convenience cohort of critical care survivors (n=77).
On admission patients had a median of 9 (5;12) medicines, of which a median of 3 (2;5) were high-risk medicines. Polypharmacy (5-9 medicines) and hyperpolypharmacy (≥10 medicines) occurred in 80.7% (615/762) and 43.2% (329/762) of patients, respectively. A degree of frailty was the standard (median CFS 4 (3;5)) with 45.7% (348/762) CFS 4-5 and 20% (153/762) CFS ≥6. The patient median CFS increased by 1 with polypharmacy classification increments (p<0.001). In the survivor cohort, a median of 6 (4;8) and 5 (4;8) medication changes occurred on critical care and hospital discharges, respectively. A minority of patients had detailed medication continuity plans on care transitions.
Polypharmacy and frailty were very common in this UK single-centre cohort of older emergency critical care patients. There was a significant association between the degree of polypharmacy and frailty score. The critical care pathway created extensive changes in patient medication therapy. Medication changes on care transitions often lacked detailed documentation.
将复杂和虚弱的患者收治到重症监护病房是很常见的。关于重症监护患者的临床脆弱性与多药治疗之间的关系,以及重症监护入院如何影响多药治疗,我们知之甚少。我们旨在:(1)描述一个老年急诊重症监护患者队列中临床脆弱性和多药治疗的程度和关系,以及(2)描述重症监护途径对患者多药治疗措施的影响。
对在 2016 年 3 月至 2018 年 2 年间,作为急症入住英国一家大型学术医院普通重症监护病房的所有年龄≥70 岁的患者进行回顾性评估(n=762)。描述了患者的临床虚弱量表(CFS)和入院时的多药治疗措施,并对其相关性进行了检验。在重症监护幸存者的随机选择便利队列中(n=77)分析了药物变化和护理过渡的记录。
入院时,患者的中位数为 9(5;12)种药物,其中中位数为 3(2;5)种为高风险药物。分别有 80.7%(615/762)和 43.2%(329/762)的患者存在多药治疗(5-9 种药物)和超多药治疗(≥10 种药物)。患者的虚弱程度为标准(中位数 CFS 4(3;5)),其中 45.7%(348/762)的 CFS 为 4-5,20%(153/762)的 CFS≥6。患者的 CFS 中位数随多药治疗分类的增加而增加 1(p<0.001)。在幸存者队列中,在重症监护和出院时,中位数分别有 6(4;8)和 5(4;8)种药物变化。在护理过渡时,只有少数患者有详细的药物连续性计划。
在英国这家单中心的老年急诊重症监护患者队列中,多药治疗和虚弱非常常见。多药治疗程度和虚弱评分之间存在显著相关性。重症监护途径对患者的药物治疗方案产生了广泛的影响。护理过渡时的药物变化往往缺乏详细的记录。